[go: up one dir, main page]

OA11084A - 2-Amino--6-(2-substituted-4-phenoxy)-substituted- pyridines - Google Patents

2-Amino--6-(2-substituted-4-phenoxy)-substituted- pyridines Download PDF

Info

Publication number
OA11084A
OA11084A OA9900173A OA9900173A OA11084A OA 11084 A OA11084 A OA 11084A OA 9900173 A OA9900173 A OA 9900173A OA 9900173 A OA9900173 A OA 9900173A OA 11084 A OA11084 A OA 11084A
Authority
OA
OAPI
Prior art keywords
alkyl
formula
nmr
disease
nitrogen
Prior art date
Application number
OA9900173A
Other languages
English (en)
Inventor
John Adams Lowe Iii
Jolanta Nowakowski
Robert Alfred Volkmann
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA11084A publication Critical patent/OA11084A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA9900173A 1997-02-10 1999-08-06 2-Amino--6-(2-substituted-4-phenoxy)-substituted- pyridines OA11084A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3753397P 1997-02-10 1997-02-10

Publications (1)

Publication Number Publication Date
OA11084A true OA11084A (en) 2002-03-15

Family

ID=21894849

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900173A OA11084A (en) 1997-02-10 1999-08-06 2-Amino--6-(2-substituted-4-phenoxy)-substituted- pyridines

Country Status (44)

Country Link
US (2) US20010007873A1 (pt)
EP (1) EP0958282B1 (pt)
JP (1) JP3505189B2 (pt)
KR (1) KR100460399B1 (pt)
CN (3) CN1246848A (pt)
AP (1) AP833A (pt)
AR (1) AR011117A1 (pt)
AT (1) ATE271544T1 (pt)
AU (1) AU744313B2 (pt)
BG (1) BG103633A (pt)
BR (1) BR9811093A (pt)
CA (1) CA2277990C (pt)
CO (1) CO4920225A1 (pt)
CZ (1) CZ292135B6 (pt)
DE (1) DE69825147T2 (pt)
DK (1) DK0958282T3 (pt)
DZ (1) DZ2414A1 (pt)
EA (1) EA003834B1 (pt)
ES (1) ES2224354T3 (pt)
GT (1) GT199800032A (pt)
HN (1) HN1998000030A (pt)
HR (1) HRP980069A2 (pt)
HU (1) HUP0000762A3 (pt)
IL (1) IL130898A0 (pt)
IS (1) IS5118A (pt)
MA (1) MA27676A1 (pt)
MY (1) MY120976A (pt)
NO (1) NO314803B1 (pt)
NZ (2) NZ336623A (pt)
OA (1) OA11084A (pt)
PA (1) PA8446301A1 (pt)
PE (1) PE58599A1 (pt)
PL (1) PL335161A1 (pt)
PT (1) PT958282E (pt)
SI (1) SI0958282T1 (pt)
SK (1) SK101199A3 (pt)
TN (1) TNSN98024A1 (pt)
TR (1) TR199901917T2 (pt)
TW (1) TW458969B (pt)
UA (1) UA64740C2 (pt)
UY (1) UY24881A1 (pt)
WO (1) WO1998034919A1 (pt)
YU (1) YU35699A (pt)
ZA (1) ZA981017B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
EP1084109B1 (en) * 1998-06-03 2005-01-26 Pfizer Products Inc. 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors
SK1702001A3 (en) * 1998-08-11 2003-02-04 Pfizer Prod Inc New pharmaceutical uses for NOS inhibitors
SE9803710L (sv) 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
DE60003893T2 (de) 1999-02-25 2004-02-05 Pfizer Products Inc., Groton 2-aminopyridine mit kondensierten ringsubstituenten
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
GB0019006D0 (en) * 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
US20030232739A1 (en) * 2001-08-15 2003-12-18 Pfizer Inc. Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
DOP2002000467A (es) * 2001-10-10 2003-04-15 Pfizer Prod Inc 2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas
US6803470B2 (en) 2001-10-10 2004-10-12 Pfizer Inc 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
US7045652B2 (en) * 2002-07-03 2006-05-16 Pfizer Inc Processes for preparing substituted aryl boronic acids
US20040092741A1 (en) * 2002-11-08 2004-05-13 Pfizer Inc Substituted pyridines via boronic acid coupling
WO2005007627A1 (ja) * 2003-07-18 2005-01-27 Nihon Nohyaku Co., Ltd. フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤
JP2008545616A (ja) * 2005-02-21 2008-12-18 プロキシマジェン エルティーディー ジスキネジーの阻害または治療
GB0607196D0 (en) * 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
WO2008080938A1 (en) * 2006-12-28 2008-07-10 Basf Se Use 2-substituted pyridines for cancer treatment
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
CA2900348C (en) 2013-02-28 2021-06-22 Sk Chemicals Co., Ltd. Tricyclic compound and use thereof
CA2928951C (en) * 2013-11-07 2023-10-17 The University Of Kansas Biphenylamide derivative hsp90 inhibitors
KR102137861B1 (ko) * 2014-08-13 2020-07-24 메이지 세이카 파루마 가부시키가이샤 결정성 항백선균약 및 그 제조 방법
CN106265640B (zh) * 2016-08-11 2019-05-14 吉林大学 Appa在制备治疗糖尿病肾病药物中的应用
CN108069831B (zh) * 2018-01-25 2020-11-24 上海恩氟佳科技有限公司 一种合成2,3-二甲基-4-氟苯酚的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5704594A (en) * 1992-12-18 1994-07-19 Wellcome Foundation Limited, The Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
EP0897912A1 (en) * 1993-10-21 1999-02-24 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
WO1996018616A1 (en) * 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
KR100313641B1 (ko) * 1996-03-29 2002-02-19 디. 제이. 우드, 스피겔 알렌 제이 6-페닐피리딜-2-아민유도체

Also Published As

Publication number Publication date
CN1523015A (zh) 2004-08-25
HRP980069A2 (en) 1998-12-31
IS5118A (is) 1999-07-29
DZ2414A1 (fr) 2003-01-04
EP0958282A1 (en) 1999-11-24
CZ276999A3 (cs) 2000-05-17
AR011117A1 (es) 2000-08-02
DE69825147D1 (de) 2004-08-26
PL335161A1 (en) 2000-04-10
PA8446301A1 (es) 2000-05-24
EP0958282B1 (en) 2004-07-21
ATE271544T1 (de) 2004-08-15
CO4920225A1 (es) 2000-05-29
TR199901917T2 (xx) 1999-12-21
DE69825147T2 (de) 2005-08-04
NZ518345A (en) 2005-02-25
EA199900632A1 (ru) 2000-02-28
CA2277990C (en) 2006-08-01
CN1515554A (zh) 2004-07-28
AP833A (en) 2000-05-10
IL130898A0 (en) 2001-01-28
GT199800032A (es) 1998-02-11
CZ292135B6 (cs) 2003-08-13
AU5572798A (en) 1998-08-26
NZ336623A (en) 2000-11-24
HN1998000030A (es) 1998-10-22
US20030162765A1 (en) 2003-08-28
BG103633A (bg) 2000-11-30
NO993823L (no) 1999-08-09
US20010007873A1 (en) 2001-07-12
KR100460399B1 (ko) 2004-12-08
BR9811093A (pt) 2000-07-18
SK101199A3 (en) 2000-10-09
NO993823D0 (no) 1999-08-09
MY120976A (en) 2005-12-30
TNSN98024A1 (fr) 2005-03-15
DK0958282T3 (da) 2004-11-29
TW458969B (en) 2001-10-11
CA2277990A1 (en) 1998-08-13
MA27676A1 (fr) 2006-01-02
KR20000070803A (ko) 2000-11-25
YU35699A (sh) 2002-06-19
UY24881A1 (es) 2000-12-29
SI0958282T1 (en) 2005-02-28
AU744313B2 (en) 2002-02-21
JP3505189B2 (ja) 2004-03-08
CN1246848A (zh) 2000-03-08
ZA981017B (en) 1999-08-10
PT958282E (pt) 2004-11-30
ES2224354T3 (es) 2005-03-01
HUP0000762A3 (en) 2000-10-30
WO1998034919A1 (en) 1998-08-13
EA003834B1 (ru) 2003-10-30
UA64740C2 (uk) 2004-03-15
JP2000509408A (ja) 2000-07-25
HUP0000762A2 (hu) 2000-09-28
PE58599A1 (es) 1999-06-12
NO314803B1 (no) 2003-05-26

Similar Documents

Publication Publication Date Title
OA11084A (en) 2-Amino--6-(2-substituted-4-phenoxy)-substituted- pyridines
EP2315746A1 (en) Urea derivatives as antibacterial agents
EP3658547B1 (en) Process for preparing n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide
EP2664617A1 (en) Method of making a 2,6-diaryl piperidine derivative
JP2022528919A (ja) Malt1阻害剤としての尿素誘導体
MXPA01008671A (es) 2-aminopiridinas que contienen sustituyentes de tipo anillo condensado.
JP4865559B2 (ja) 鎮痛活性を有するインダゾール
AU769233B2 (en) 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
OA11557A (en) 2-Aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors.
MXPA99007398A (en) 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
EP1434624A1 (en) 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors
AU2017258665A1 (en) Process for the preparation of herbicidal compounds
AU2002341234A1 (en) 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors
MXPA00002028A (en) Branched alkoxy-subsituted 2-aminopyridines as nos inhibitors
WO2010092287A1 (fr) Derives de n-[(6-aza-bicyclo[3.2.1]oct-1-yl)-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique